The Impact of COVID-19 Pandemic on Patients with Schizophrenia

Abstract

The fear of transmission of COVID-19 infection has contributed to the occurrence of anxiety and depression in individuals who have not previously suffered from mental illness, and to the worsening of symptoms in patients previously diagnosed with mental illness. It has been shown that patients with schizophrenia have an increased risk of contracting COVID-19, are more often hospitalized and have a higher mortality rate. This is correlated with many comorbidities, tobacco consumption, and extensive use of medications. It has been noted that there is a connection between the immune and inflammatory response of COVID-19 and schizophrenia. Healthcare inequality and stigma result in a poorer outcome of COVID-19 in persons suffering from mental illness. The COVID-19 pandemic can cause a worsening of psychotic symptoms and the reoccurrence of relapses in those with a prior mental illness diagnosis. Additionally, it has been noted that social seclusion can cause a decline in psychological wellbeing, leading to increased levels of stress and anxiety. To ensure that patients with schizophrenia receive uninterrupted care and minimize the risk of infection, telemedicine offers an optimal solution; however, for more severe cases, physical visits remain imperative. Patients with schizophrenia are particularly exposed to contraction and potential death from COVID-19 and require the support of society and medical professionals to help eliminate the stigma they often face, and guarantee equal access to healthcare.